Cardiovascular disease (CVD) has long been the leading cause of death worldwide. In 2013, CVD accounted for 31% of all deaths [@bib1], representing a 41.7% increase since 1990 [@bib2]. Of the conditions classified as CVD, myocardial infarction (MI) and peripheral artery disease (PAD) are associated with significant morbidity and mortality. In the United States alone, approximately 8.5 million individuals are afflicted by PAD [@bib3], and an estimated 660,000 individuals experience a new MI and 305,000 have a recurrent MI annually [@bib4]. The resulting negative left ventricular (LV) remodeling and heart failure (HF) or critical limb ischemia (CLI) and potential limb amputation that occurs in MI and PAD patients, respectively, significantly reduces the life expectancy of these individuals. Therefore, treatments for repairing ischemic damage and restoring muscle function for MI and PAD are needed.

Although current medical interventions mitigate some symptoms, they fail to prevent HF post-MI or remain unavailable for many patients with PAD. The current gold standard for MI relies on percutaneous coronary intervention (PCI) or a coronary artery bypass graft to alleviate the occluded coronary artery. However, the ischemic damage is not addressed, which subsequently leads to negative LV remodeling and ultimately HF. For PAD, stenting and balloon angioplasty treat severe conditions, but restenosis often occurs. In fact, restenosis rates for stenting and balloon angioplasty with optional stenting were both over 45% 2 years after the initial intervention [@bib5]. Similar to MI patients, the extent of occlusions and resulting ischemic damage fluctuates greatly among PAD patients, ranging from intermittent claudication to CLI. This variability contributes to difficulties with identifying a widespread treatment, demonstrated by only 40% of individuals being eligible for existing surgical procedures [@bib6]. Ultimately, new medical interventions must be developed to overcome the limitations of current approaches for MI and PAD.

Within the past 15 years, biomaterials have emerged as a therapeutic approach to fill the existing gaps in treatments for MI and PAD ([Table 1](#tbl1){ref-type="table"}). To maximize therapeutic efficacy, biomaterials should be engineered according to specific design criteria, including material selection, mechanical properties, chemical properties, and so on. Design parameters and accompanying modifications are shown in [Figure 1](#fig1){ref-type="fig"}. This review will highlight design criteria and mechanisms of actions for biomaterial applications in PAD and MI patients and will discuss the progress toward engineering effective biomaterial-based therapies. These biomaterial applications will include material-alone approaches, as well the use of biomaterials as delivery vehicles for acellular biologics ([Central Illustration](#undfig2){ref-type="fig"}).Table 1Acellular Injectable Biomaterial Applications for MI and PADMaterialMI/PADMaterial FormBiologics DeliveredModificationsRef. \#AlginateMIHydrogelHGF, IGF-1; PDGF-BB, VEGF-AConjugation with cell adhesion peptides; sulfation; copolymerization with fibrin[@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib61], [@bib65]PADHydrogel; microspheresIGF-1, VEGF; HGF; VEGF-F; SDF-1Combination with poly(d,l-lactide-co-glycolide) microspheres; sulfation; combination with collagen hydrogel[@bib44], [@bib106], [@bib109], [@bib113]ChitosanMIHydrogelbFGF; FGF-2Introduction of azide[@bib60], [@bib70]PADHydrogelFGF-2Combination with lactose moieties and a periodate-oxidized IO~4~ heparin solution[@bib100]CollagenMIHydrogelN/AN/A[@bib20], [@bib22]PADHydrogel; microsponges; microspheresSDF-1; bFGF; bFGF, HGFCombination with alginate microspheres[@bib103], [@bib106], [@bib111]Decellularized myocardial ECMMIHydrogelN/AN/A[@bib28], [@bib30]Decellularized pericardial ECMMIHydrogelbFGF; HGFN/A[@bib67], [@bib68]Decellularized skeletal muscle ECMPADHydrogelN/AN/A[@bib85], [@bib93]Decellularized small intestine submucosa ECMMIParticles; hydrogelN/AN/A[@bib25], [@bib34]DextranMIMicroparticlesHGFAcetalated[@bib69]PADNanoparticlesVEGFCopolymerization with gelatin[@bib114]FibrinMIHydrogelbFGFDelivery with heparin-conjugated PLGA nanospheres; copolymerization with alginate[@bib13], [@bib18], [@bib19], [@bib22], [@bib63]PADHydrogel; particlesFGF-2Conjugation with heparin[@bib91], [@bib92], [@bib115]FucoidanPADHydrogelFGF-2N/A[@bib110]GelatinMIMicrospheresbFGF; IGF-1, VEGFN/A[@bib59], [@bib62], [@bib64], [@bib66]PADMicrospheres; hydrogelFGF-4; bFGF; FGF-2; G-CSFCrosslinking with poly-L-glutamic acid, crosslinking with poly-L-lysine[@bib97], [@bib99], [@bib101], [@bib102], [@bib104], [@bib105], [@bib107], [@bib108], [@bib112], [@bib116]Hyaluronic acidMIHydrogelrTIMP-3Methacrylation; crosslinking with hydroxyethyl methacrylate; acrylation, crosslinking with PEG tetra-thiol[@bib23], [@bib32], [@bib33], [@bib71]KeratinMIHydrogelN/AN/A[@bib29]MatrigelMIHydrogelN/AN/A[@bib22], [@bib26]PEG basedMIHydrogelVEGF; HGF, VEGF; HGF, IGF-1; EPOCrosslinking with amide- succinimidyl glutarate; crosslinking with succinimidyl glutaramide or amine; derivatization with vinyl sulfone; copolymerization with polycaprolactone; copolymerization with poly(δ-valerolactone); functionalization with cell adhesion peptides; coupling with UPy units; combination with α-cyclodextrin and copolymerization with polycaprolactone[@bib17], [@bib21], [@bib27], [@bib31], [@bib72], [@bib73], [@bib74]Peptide nanofibersMIHydrogelVEGF; IGF-1; FGF-2, PDGF-BBBiotinylation of peptides[@bib76], [@bib80], [@bib82]PLGA basedMIMicroparticles, nanoparticlesNRG-1, FGF-1; VEGF; IGF-1Copolymerization with poly\[(D,L-lactide-co-glycolide)-co-PEG\][@bib75], [@bib77], [@bib78], [@bib83]PADNanoparticlesFGF-2N/A[@bib98]PNIPAAm basedMIHydrogelbFGFCombination with dextran chains and poly(ε-caprolactone)-2-hydroxylethyl methacrylate; copolymerization with acrylic acid and hydroxyethyl methacrylate-poly(trimethylene carbonate); copolymerization with propylacrylic acid and butyl acrylate[@bib35], [@bib36], [@bib79]UPyMIHydrogelHGF, IGF-1N/A[@bib81][^1]Figure 1Design Variables to Be Considered When Developing Biomaterial Applications for MI and PADTo successfully translate biomaterials to the clinic, specific design criteria must be considered to ensure that the final product remains biocompatible while maintaining its full therapeutic efficacy. Extensive engineering of a biomaterial can maximize therapeutic benefits, but these benefits must counterbalance accompanied costs and manufacturing difficulties. MI = myocardial infarction; miRNA = microribonucleic acid; PAD = peripheral artery disease.Central IllustrationAcellular Biomaterial Therapeutics for Repairing Ischemic Damage From MI and PADPreclinical studies have currently been investigating biomaterial-alone therapies or biomaterials loaded with therapeutics as potential treatment options for myocardial infarction (MI) and peripheral artery disease (PAD). Other therapeutics, like microribonucleic acids (miRNAs) or exosomes, also show promise as factors to be delivered with a biomaterial. However, the success of these therapies largely depends on satisfying specific design criteria.

Designing Acellular Injectable Biomaterial Therapies for MI {#sec1}
===========================================================

Biomaterials alone {#sec1.1}
------------------

In general, biomaterials designed for MI have demonstrated capabilities to prevent negative LV remodeling, including increasing infarct wall thickness and decreasing LV volume, fibrosis, and infarct size [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36]. Additionally, many biomaterials also promote other beneficial processes like neovascularization. Since the first papers published in 2004 [@bib18], [@bib19], studies in this area have significantly increased; a detailed coverage of individual studies can be found in other reviews [@bib37], [@bib38], [@bib39].

For treating MI, important design criteria include material spread, delivery, and material selection, which affects chemical, mechanical, and degradation properties. Beginning with material selection, biomaterials can be divided into 2 classes: natural and synthetic biomaterials. Natural biomaterials can be derived from biological sources like alginate from brown algae [@bib9], [@bib11], [@bib15], [@bib16], collagen from connective tissue [@bib20], [@bib22], [@bib40], or decellularized extracellular matrix (ECM) isolated from various tissues and organs [@bib28], [@bib41], [@bib42]. Several synthetic polymers like variations of poly(N-isopropylacrylamide) [@bib35], [@bib36] and synthetically modified naturally derived materials such as methacrylated hyaluronic acid (HA) have also been tested [@bib23], [@bib32]. For eventual translation into MI patients, factors like biocompatibility, manufacturing ease, and cost must be considered. For naturally derived biomaterials, 2 main advantages include the ability to mimic native biochemical cues and potentially more cost-effective manufacturing by avoiding complex chemical synthesis. However, naturally derived materials can suffer from batch-to-batch variability due to variations in biological sources. With synthetic biomaterials, the material properties can be customized more extensively, and there are fewer issues with limited availability of raw materials. Conversely, disadvantages include potential biocompatibility issues and difficulty replicating the complex native tissue structure. Regardless of these advantages and disadvantages, most research for treating MI has utilized naturally derived biomaterials or synthetically modified derivatives [@bib37], [@bib38], [@bib39].

Other factors to be considered for material selection include chemistry and mechanical properties, which can affect important cellular processes upon injection. These cellular responses, forming the basis for 1 proposed mechanism of action, include neovascularization, shifts in inflammatory/immune cells, decreases in cell death, changes in fibroblast activity (i.e. matrix production), and/or recruitment and differentiation of stem or progenitor cells. [Figure 2](#fig2){ref-type="fig"} displays the cellular response of varying biomaterials upon injection [@bib16], [@bib23], [@bib28], [@bib35], [@bib43], [@bib44]. Although the exact material properties leading to these outcomes are still unknown, chemical properties can be engineered accordingly, or biomaterials with the necessary properties should be selected. Naturally derived biomaterials, like collagen or decellularized ECM, have adhesion proteins, including fibronectin, fibrinogen, laminin, or collagen, to promote cell attachment. Using collagen and fibrin glue injections, neovascularization processes were stimulated [@bib19], [@bib22], while porcine-derived myocardial ECM hydrogels promoted infiltration of endothelial cells, smooth muscle cells, and progenitor cells [@bib30], [@bib41]. However, for biomaterials lacking adhesion peptides, cell adhesion peptide sequences, like arginine-glycine-asparagine, can be added to improve cell adhesion, as was done by Yu et al. [@bib16] with alginate. This modification resulted in significantly increased arteriole density relative to phosphate-buffered saline and unmodified alginate control subjects after 5 weeks post-treatment in a rat MI model.Figure 2Cellular Responses to Injected BiomaterialsUpon injection of a biomaterial, the resulting cellular responses can largely affect eventual tissue regeneration. Hematoxylin and eosin images are shown for **(A)** a decellularized myocardial extracellular matrix hydrogel (3 days post-injection), **(B)** acetalated dextran microparticles (7 days post-injection), **(C)** a methacrylated hyaluronic acid hydrogel (1 day post-injection), **(D)** a poly(N-isopropylacrylamide)-based synthetic hydrogel (8 weeks post-injection), and **(E)** an alginate hydrogel (14 days post-injection). **(F)** Masson's trichrome staining shows residual alginate in a heart section 5 weeks post-injection. All tissue sections are from the heart except for **(E)**, which is skeletal muscle. **Black arrows, asterisks,** and **"G"** denote the biomaterial.Reproduced with permission from Seif-Naraghi et al. [@bib28], Suarez et al. [@bib43], Ifkovits et al. [@bib23], Fujimoto et al. [@bib35], Borselli et al. [@bib44], and Yu et al. [@bib16].

Another mechanism of action focuses on the mechanical support provided by biomaterial scaffolds, which may reduce wall stress according to LaPlace's law. Mechanical properties are well known to affect cell fate [@bib45], [@bib46] and have been shown to affect outcomes in the heart [@bib23]. However, recent studies suggest that injectable materials in the heart predominantly act through their bioactivity and/or cell response rather than a mechanical support [@bib27], [@bib47]. Moreover, many injected materials showing improvements in cardiac function are weak hydrogels with stiffnesses significantly lower than the myocardium, likely providing minimal mechanical support. One study modulating mechanical properties of a HA-based hydrogel resulted in differences in infarct size [@bib23], showing that mechanical properties of a material are indeed important; however, these results could be related to the corresponding cellular response. Although not typically a concern with naturally derived injectable hydrogels, one should also ensure that a material is not too stiff so that it negatively affects diastolic function.

Similar to chemistry and mechanical properties, degradation properties can be significantly affected by poor material choice. Variables like the pH (which is acidic in an acute infarct [@bib48]), temperature, and mechanical environment of the implanted biomaterial can also affect the degradation time. For most biomaterials tested to date, degradation times were inherent; however, it is possible to modify degradation rate though modulating chemistry, concentration, crosslinker density, porosity, and hydrophobicity. Burdick et al. [@bib49] investigated the effects of HA macromer concentration, whereas Lee et al. [@bib50] demonstrated the effect of crosslinking on degradation rates. Altogether, the inherent chemical, mechanical, and degradation properties of the chosen biomaterial can greatly influence the long-term therapeutic efficacy.

One critical, but often overlooked, design criterion is the delivery method for biomaterial therapies. Although injectable biomaterial-alone approaches and biomaterial patches [@bib40], [@bib42], [@bib51] have gained attention for their therapeutic benefits, injectable versions have the advantage of a minimally invasive delivery route [@bib52]. Current delivery approaches include intracoronary infusion via a balloon infusion catheter, direct epicardial injection with a single- or double-barrel syringe, or transendocardial injection via a catheter ([Figure 3](#fig3){ref-type="fig"}) [@bib53]. Epicardial injections have the most control over delivery but often require an invasive surgical procedure, which is likely to complicate widespread use. Although the 2 remaining methods are minimally invasive, they have disadvantages, including relying on leaky acute MI vasculature for intracoronary delivery and needing specialized training for transendocardial delivery. Obviating the need for an invasive surgery with general anesthesia has, however, resulted in the majority of injectable therapeutics, including biomaterials, being delivered via catheter-based approaches in clinical trials. For catheter delivery, the material must be hemocompatible given embolization risks since the material is injected into a coronary with an infusion approach and is known to leak into the LV chamber with transendocardial injections. In addition, the material must be designed to have appropriate gelation kinetics to travel through a long, small-diameter catheter (typically 27-gauge) and gel in the infarct, but not in the blood stream. The rapid gelation and/or lack of hemocompatibility have prevented most injectable biomaterials from being delivered with these more translationally relevant methods. For instance, an alginate formulation that is being studied in HF patients was not initially designed for catheter delivery and, therefore, must be delivered via an invasive surgical approach [@bib7], [@bib12]. In particular, multiple injections required with transendocardial injections create a unique design constraint not common with other injectable biomaterial applications.Figure 3Delivery Methods for Biomaterial-Based Applications in MIWhen designing a biomaterial approach for MI, the importance of the delivery route is often underestimated. **(A)** Intracoronary infusion via a balloon infusion catheter relies on leaky acute MI vasculature for delivery, whereas **(C)** transendocardial injection via a catheter requires specialized training. However, neither of these minimally invasive methods requires an invasive surgery, unlike **(B)** direct epicardial injections.Reproduced with permission from Stamm et al. [@bib53].

Upon injection, other variables, like material spread, have also been studied to avoid dangerous side effects like arrhythmias. A study by Suarez et al. [@bib31] looked at the effects of interstitial spread with poly(ethylene glycol)-based hydrogels and did not discover changes to action potential propagation with high spreading materials. However, significant delays as well as a reduction in gap junction density were found with materials that were quick gelling and formed a bolus, suggesting that they may be a potential substrate for arrhythmias [@bib31]. This study was only done in rats, though, and additional studies are needed in large animals, as well as with different biomaterials.

By harnessing the potential of naturally derived biomaterials, several studies have progressed into clinical trials ([Table 2](#tbl2){ref-type="table"}). Using calcium crosslinked alginate hydrogels, the PRESERVATION I (IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction) trial ([NCT01226563](https://clinicaltrials.gov/ct2/show/NCT01226563){#intref0010}) included patients who had experienced a large MI and underwent successful primary PCI within 48 h of symptom onset, whereas the AUGMENT-HF (A Randomized, Controlled Study to Evaluate Algisyl-LVR as a Method of Left Ventricular Augmentation for Heart Failure) trial ([NCT01311791](https://clinicaltrials.gov/ct2/show/NCT01311791){#intref0015}) included HF patients, with approximately one-half of the participants having experienced a previous MI. PRESERVATION I participants received 4-ml infusions of either saline or the alginate solution 2 to 5 days post-PCI into the occluded artery via catheter-based intracoronary infusion [@bib14]. Despite observing prevention and a reversal of LV dilation and increased scar thickness in a swine acute MI model [@bib11] and conservation of the LV end-diastolic volume index, LV end-systolic volume index, and ejection fraction (EF) with 2-ml infusions of the alginate hydrogel in the Phase I trial [@bib8], no differences were seen between the treated and control groups in terms of the LV end-diastolic volume index after 6 months. It has been suggested that this was a result of too little material being utilized for larger infarcts, timing of treatment administration, and/or the inability of the material to reach the infarct zone due to microvascular occlusions. Another significant possibility is that cells do not adhere readily to alginate, and thus it has minimal bioactivity, which could have resulted in a lack of improvements. In the AUGMENT-HF trial, significantly increased peak VO~2~ levels and 6-min walk test distance were seen at 3, 6, and 12 months after intervention via 10 to 19 0.3-ml intramyocardial injections through a limited left thoracotomy approach compared with standard medical therapy alone [@bib7], [@bib12]. However, compared to improved LV function and quality of life with alginate administration during cardiac bypass surgery or valve replacement/repair in phase I studies [@bib10], no significant changes in the EF, LV end-diastolic diameter, or LV end-systolic diameter were seen in phase II. The latest biomaterial-alone therapy to advance into clinical trials is based on the preclinical studies done by Seif-Naraghi et al. [@bib28] with an injectable decellularized myocardial ECM hydrogel in a porcine MI model. At 3 months post-injection, pigs treated with the ECM hydrogel showed an increase in global and regional cardiac function compared with control animals. In addition, the myocardial matrix hydrogel increased cardiac muscle compared with noninjected and saline-injected animals. Currently in a phase I clinical trial ([NCT02305602](https://clinicaltrials.gov/ct2/show/NCT02305602){#intref0020}), VentriGel (Ventrix, Inc., San Diego, California) is being delivered via transendocardial injections with a MyoStar catheter (Biosense Webster, Diamond Bar, California) in patients who experienced a previous MI (60 days to 3 years since the event).Table 2Clinical Trials for Injectable Biomaterials in MI and PADMaterialProduct Name (Identifier \#)Trial PhaseMI/PADStudy DesignResultsRef. \#DesignControlPatient PopulationDeliveryGelatin microspheres with bFGFN/AN/APADNonrandomizedNonePatients with CLI, no option of medical or surgical treatment (7 total)Single intramuscular injection (200 μg)Significant improvements in 6-min walk distance, blood perfusion, transcutaneous oxygen pressure, and rest pain scale compared with pre-treatment values[@bib112]AlginateAlgisyl-LVR ([NCT00847964](https://clinicaltrials.gov/ct2/show/NCT00847964){#intref0025})IMINonrandomizedNoneHF patients (9 total)Intramyocardial injections during cardiac bypass surgery or valve replacement/repair (9--15 injections, 0.25--0.35 ml each)Improved LV function and quality of life[@bib10]Algisyl-LVR ([NCT01311791](https://clinicaltrials.gov/ct2/show/NCT01311791){#intref0030})II (AUGMENT-HF)MIRandomized, single-blindStandard medical therapy aloneHF patients, approximately one-half with previous MI (n = 78)Intramyocardial injections via limited left thoracotomy (10--19 injections, 0.3 ml each)Significant increases in peak VO~2~ levels and 6-min walk test distance, no changes in EF, LV end-diastolic diameter, or LV end-systolic diameter[@bib7], [@bib12]AlginateBL-1040 ([NCT00557531](https://clinicaltrials.gov/ct2/show/NCT00557531){#intref0035})IMINonrandomizedNoneExperienced moderate to large MI, underwent successful primary PCI (n = 27)Catheter-based intracoronary infusion (2 ml)Preserved LVEDV index, LVESV index, and LVEF[@bib8]IK-5001 ([NCT01226563](https://clinicaltrials.gov/ct2/show/NCT01226563){#intref0040})II (PRESERVATION I)MIRandomized, double-blindPlacebo (saline)Experienced large MI, underwent successful primary PCI (n = 303)Catheter-based intracoronary infusion (4 ml)No differences in terms of LVEDV index[@bib14]Decellularized myocardial ECM hydrogelVentriGel ([NCT02305602](https://clinicaltrials.gov/ct2/show/NCT02305602){#intref0045})IMINonrandomizedNoneExperienced previous MI, 60 days to 3 years since event (18 patients projected)Transendocardial delivery via MyoStar catheterOngoing[@bib28][^2]

Compared with other emerging therapeutics for MI, biomaterials also represent a potentially more promising approach in terms of translation and commercialization [@bib54]. Biomaterial hydrogels allow for more precise treatment since the material remains localized upon injection unlike small molecule or protein therapeutics, which rapidly diffuse away from the injection site [@bib55], [@bib56], or cell injections, which also migrate and have poor survival [@bib57], [@bib58]. Lastly, biomaterials alone represent a more cost-effective option since incorporation of additional therapeutics can dramatically increase expenses. By incorporating and understanding some of the design criteria described in the previous text, several biomaterial-alone approaches have yielded positive results, leading to a few clinical trials. To advance the field and progress into greater numbers of clinical trials, it is imperative that researchers consider these design criteria from the beginning. It will also be important to elucidate the mechanisms of action of these materials, which will lead to improved material generation.

Biomaterials and growth factors {#sec1.2}
-------------------------------

In addition to utilizing biomaterial-alone approaches, codelivery with additional acellular biologics, predominantly growth factors, has been employed ([Table 1](#tbl1){ref-type="table"}) [@bib59], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72], [@bib73], [@bib74], [@bib75], [@bib76], [@bib77], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83]. A major challenge for growth factor therapeutics has been rapid diffusion upon delivery, but biomaterial delivery vehicles can prolong the release rate and improve localization by selecting or designing biomaterials to elicit the desired release profile. Additionally, using biomaterials can decrease the costs of incorporating growth factors since smaller quantities are required. Generally, the material form, degradation properties, and chemistry are paramount for enhancing rate of release and localization; therefore, material selection and additional modifications must be analyzed to identify the optimal delivery vehicle.

For physical and degradation properties, biomaterials must retain and then gradually release growth factors upon delivery. The microscale or nanoscale architecture of hydrogels, microparticles, or nanoparticles significantly contributes to this tunable release ([Figure 4](#fig4){ref-type="fig"}) [@bib29], [@bib67], [@bib78], [@bib84], [@bib85], [@bib86]; results for individual studies can be found in another review [@bib87]. With hydrogels and particles, the architecture provides small pores for slow growth factor release, and gradual degradation of the material contributes to a more complete release. Through the gelation of hydrogels or targeted delivery with particles, growth factors are localized to a region of interest and cannot diffuse rapidly upon delivery. Additionally, regulated delivery prevents systemic side effects due to uncontrolled diffusion, demonstrated by Lin et al. [@bib82], with significantly reduced vascular leakage resulting from codelivery of high doses of vascular endothelial growth factor (VEGF) with self-assembling peptide nanofibers. Although a longer release may seem favorable, this is not true for all growth factors. In fact, complex processes, like angiogenesis, require precise timing and order for the delivery of therapeutics [@bib84], [@bib88]. Suarez et al. [@bib69] demonstrated this importance with an engineered hepatocyte growth factor (HGF) fragment diffusing at varying rates from acetalated dextran microparticles in a rat MI model due to different degradation profiles, showing that it was most effective when delivered over 3 days compared with 1.5 or 2.5 weeks.Figure 4Structures of Biomaterials for MI and PAD ApplicationsBiomaterial structures dictate important parameters including degradation and controlled release of therapeutics. The architecture, shown by scanning electron micrographs, varies among hydrogels, such as **(A)** keratin, **(B)** porcine-derived skeletal muscle extracellular matrix (ECM), **(C)** porcine-derived pericardial ECM, **(D)** collagen, **(E)** alginate, or **(F)** fibrin. Additionally, hydrogel architecture differs from particles like **(G)** poly(lactic-*co*-glycolic acid) microparticles or **(H)** acetalated dextran microparticles. Reproduced with permission from Shen et al. [@bib29], DeQuach et al. [@bib85], Seif-Naraghi et al. [@bib67], Freeman et al. [@bib84], Losi et al. [@bib86], Formiga et al. [@bib78], and Suarez et al. [@bib43]. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Instead of solely relying on the architecture of the biomaterial to control the retention and release, biomaterials can also be modified to encourage binding and retention of growth factors. This can be achieved through the presence of sulfated glycosaminoglycans or sulfation of a biomaterial to contribute to a slower release profile. Binding of growth factors can also yield higher therapeutic efficacy by increasing stability and activity, as was reviewed by Zisch et al. [@bib89] for the release of angiogenic growth factors. Ruvinov et al. [@bib65] also showed this with an affinity-binding alginate biomaterial consisting of insulin-like growth factor-1 and HGF bound by alginate-sulfate interactions in a rat MI model. After 4 weeks, the fibrotic area was significantly reduced and the relative scar thickness, blood vessel density, and average individual blood vessel area were significantly increased. With decellularized ECM hydrogels, however, sulfation is unnecessary because sulfated glycosaminoglycans are still present after decellularization [@bib90]. In 2 studies by Seif-Naraghi et al. [@bib67] and Sonnenberg et al. [@bib68], decellularized pericardial ECM hydrogels were mixed with basic fibroblast growth factor (bFGF) and an engineered HGF fragment, respectively. Both studies showed significantly increased arteriole density in animals treated with the ECM hydrogels and growth factors over growth factors delivered in saline, whereas Sonnenberg et al. [@bib68], also observed an increased fractional area change.

Research conducted on growth factors encapsulated in biomaterials for treating MI has made several advances into large animal models. Liu et al. [@bib64] utilized bFGF incorporated into gelatin microspheres in a pig infarct model, which yielded increases in EF and vascular density. Mentioned earlier, Lin et al. [@bib82] injected self-assembling peptide nanofibers mixed with VEGF into a porcine MI model and saw improvements in fractional shortening and capillary and arteriole density and a decrease in infarct size. Finally, Koudstaal et al. [@bib81] investigated a combination of growth factors, insulin-like growth factor-1 and HGF, incorporated into a synthetic hydrogel known as ureidopyrimidinone. Diffusion of the growth factors from the ureidopyrimidinone hydrogel resulted in increased cardiac function, capillary density, and cardiac progenitor cell migration in a porcine MI model. These recent advancements have provided a strong foundation for growth factor delivery in biomaterials, but translation into the clinic has been limited, potentially due to the high cost of incorporating growth factors.

Designing Acellular Injectable Biomaterial Therapies for PAD {#sec2}
============================================================

Biomaterials alone {#sec2.1}
------------------

Current experimental treatments for PAD, including stem cells and growth factors, have not been entirely successful for many of the same reasons as MI therapeutics. Consequently, an effective, minimally invasive treatment that improves perfusion and repairs ischemic tissue damage is still needed. Biomaterial-alone therapies have shown considerable promise for repairing ischemic muscle by encouraging reperfusion and neovascularization [@bib85], [@bib91], [@bib92], [@bib93], but the success of these biomaterials as a stand-alone approach for PAD lies in satisfying particular design constraints ([Table 1](#tbl1){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). Although many of the important design properties are similar to those mentioned earlier for MI, including material selection, physical properties, and degradation properties, the design criteria vary for PAD and may fluctuate depending on the disease spectrum of the patient (i.e., intermittent claudication vs. CLI).

Similar to MI, material selection is extremely important for PAD to encourage perfusion restoration and muscle regeneration. Each biomaterial must be engineered or evaluated to promote cell infiltration and proliferation/differentiation to treat both the ischemia and muscle atrophy associated with PAD [@bib94]. As such, the materials must allow for cell adhesion and have appropriate pore size for cell migration. Several preclinical studies have investigated naturally derived biomaterials like fibrin [@bib91], [@bib92] and decellularized ECM hydrogels [@bib85], [@bib93], but synthetic biomaterials have yet to be studied in detail. Fibrin is well known to encourage vascularization and has likewise been shown in rabbit hindlimb ischemia models to increase perfusion [@bib91], [@bib92]; however, only ECM hydrogels have been evaluated for muscle repair [@bib93]. Chekanov et al. [@bib91] utilized a fibrin sealant and observed significant increases in collateral vessel development and the area occupied by capillaries compared with no treatment or saline alone. Similarly, fibrin particles used by Fan et al. [@bib92] yielded significantly augmented capillary density and perfusion recovery compared with control subjects. DeQuach et al. [@bib85] utilized an injectable porcine-derived skeletal muscle ECM hydrogel in a rat hindlimb ischemia model and showed an increase not only in vascular cells, but also in proliferating muscle cells and muscle progenitor cells. Even after selecting a naturally derived material, however, the source for that material must still be chosen. With decellularized ECM hydrogels, for example, the tissue source can affect therapeutic outcomes. In a study conducted by Ungerleider et al. [@bib93], 2 different decellularized ECM hydrogels, a porcine-derived skeletal muscle ECM and human umbilical cord ECM, were assessed in a rat hindlimb ischemia model. Although improvements in perfusion were seen for both hydrogels, the muscles injected with the skeletal muscle ECM hydrogel resembled the healthy morphology more closely than those injected with the human umbilical cord matrix, suggesting that tissue-specific cues may be important for regeneration.

The last 2 design criteria to be discussed for a biomaterial-alone approach in PAD are degradation properties and delivery. The main factor to be considered for degradation properties is whether the biomaterial will yield sufficient therapeutic improvements before it completely degrades. Because PAD most often affects the lower limbs, the mechanical environment caused by a load-bearing region can cause biomaterials to degrade more quickly. As a result, appropriate animal models must be used to generate results that are representative of the human mechanical environment. For delivery of these therapeutics, direct intramuscular injections should be utilized (ideally ≤26-gauge for patients); however, the number and timing of these injections must be determined. Due to the large surface area of the lower limbs, multiple injections of the biomaterials will be necessary. Results from small animal studies can provide insight for the appropriate concentration and required volume of injections, but these results must then be scaled up for larger animals and clinical studies. To date, limited work has been performed on developing a suitable large animal model, although a few recent studies suggest that this may be forthcoming [@bib95], [@bib96]. Overall, there is still a great deal of research to be done for biomaterial- alone approaches in PAD; however, it is a promising approach that should be pursued.

Biomaterials and growth factors {#sec2.2}
-------------------------------

Although biomaterial-alone approaches have not been extensively investigated for PAD, biomaterials have been utilized to deliver growth factors, as shown in [Table 1](#tbl1){ref-type="table"} [@bib44], [@bib97], [@bib98], [@bib99], [@bib100], [@bib101], [@bib102], [@bib103], [@bib104], [@bib105], [@bib106], [@bib107], [@bib108], [@bib109], [@bib110], [@bib111], [@bib112], [@bib113], [@bib114], [@bib115], [@bib116]. To maximize therapeutic efficacy of a biomaterial and growth factor complex, similar design criteria to MI should be applied, including selecting or engineering materials based on physical form, chemistry, and degradation properties. Physical form, such as selecting particles as opposed to hydrogels, can alter the delivery method due to the ability to engineer particles for targeting. For chemical properties, modifications like binding moieties for growth factors, such as sulfate groups, can be added to encourage longer retention. Lastly, degradation plays an equally important role in controlling retention and release since rapid degradation will lead to a similar release rate for the therapeutic payload.

By incorporating these design principles, researchers have advanced some therapies into pre-clinical studies with rabbits and larger animal models and even 1 clinical trial. An early study conducted by Kasahara et al. [@bib104] utilized gelatin microparticles to deliver fibroblast growth factor (FGF)-4 in a rabbit hindlimb ischemia model. Under vasodilatory conditions, the perfusion levels and angiographic scores were significantly higher in the gelatin/FGF-4 complex compared with gelatin or FGF-4 alone. In another study by Doi et al. [@bib99], gelatin hydrogels encapsulated with bFGF were injected intramuscularly in Japanese white rabbits 2 weeks post-hindlimb ischemia surgery. Animals treated with the gelatin and bFGF hydrogel had significantly higher perfusion levels and vascular density compared with no treatment or gelatin alone at 4 weeks post-injection. A large animal study performed in mongrel dogs by Zhao et al. [@bib116] studied bFGF encapsulated in gelatin microspheres. Significantly higher capillary densities and numbers of mature vessels were observed with the gelatin microspheres and bFGF-treated group relative to bFGF alone and empty microspheres. The final study to be mentioned includes the findings of a phase I to IIa clinical trial ([Table 2](#tbl2){ref-type="table"}). In a rabbit hindlimb ischemia model, Hirose et al. [@bib101] injected gelatin hydrogel microspheres containing bFGF and saw increased perfusion, capillary density, and collateral vessel development compared with a no treatment control group. This led to an investigation by Marui et al. [@bib112] in which biodegradable gelatin hydrogels loaded with bFGF were administered with a single intramuscular injection in patients with CLI; no controls were used for this study. At 4 and 24 weeks post-treatment, improvements were seen in the perfusion compared with values prior to treatment. By utilizing biomaterials as delivery vehicles, the growth factor release can be precisely controlled, and biomaterials can prevent degradation of growth factors to fully harness their therapeutic potential.

Designing Biomaterials as Delivery Vehicles for Emerging Therapeutics {#sec3}
=====================================================================

Although numerous studies presented in this review demonstrate the efficacy of utilizing biomaterials alone or a combination of growth factors and biomaterials for treating MI and PAD, growth factors are not the only acellular therapeutic that should be considered for biomaterial-based therapies. Biologics like erythropoietin and recombinant tissue inhibitor of matrix metalloproteinase-3 have been studied [@bib71], [@bib73], yet emerging therapeutics, such as exosomes or microribonucleic acids (miRNAs), may also enhance the beneficial properties of biomaterials, while avoiding obstacles plaguing cellular-based treatments. Previous studies investigated the efficacy of these therapeutics in MI [@bib117], [@bib118], [@bib119], [@bib120], [@bib121], [@bib122], [@bib123], [@bib124] and PAD preclinical models [@bib117], [@bib125], [@bib126], [@bib127], [@bib128], [@bib129], but limited research has been conducted to optimize delivery. For exosomes, microvesicles, and miRNAs, maximized therapeutic efficiency has been hindered by poor retention upon injection. Because these therapeutics are typically injected alone, they rapidly diffuse from the injection site, similar to growth factors, therefore leading to minimal improvements in the targeted region. One study by Hinkel et al. [@bib123] revealed the effect of catheter-based delivery compared with systemic delivery with antagomir-92a in a porcine MI model. Using a regional delivery approach, decreased infarct size and apoptosis were seen, and EF was improved compared with the systemic delivery.

This study emphasizes the importance of local delivery, but utilizing a biomaterial as a delivery vehicle is likely to further improve results. Because miRNAs are quickly degraded after injection due to the large amount of RNases circulating throughout the body, biomaterials can provide a shielded environment to maximize therapeutic effects. Additionally, the controlled release provided by biomaterials can also contribute to improved efficacy. Based on the current advancements in biomaterial-based therapies, many of the design principles discussed earlier could overcome these obstacles.

The physical form and chemistry of a biomaterial can significantly contribute to slower release kinetics in addition to providing a protected environment from degradation. By changing the physical form of the biomaterial, the release can be tuned for the specific payload, and targeting can also be incorporated with particles. Additionally, altering the biomaterial's concentration often leads to changes in pore size, which can be utilized to change the release profile. The same microscale or nanoscale architecture being modified for desired release kinetics can also be used to protect the payload from degradation. In terms of the chemistry, modifications can be made to allow for better retention of additional therapeutics or release only upon cell infiltration.

Although no biomaterial-based therapies have been published for microvesicle or miRNA delivery in MI or PAD, there are a few studies related to other applications, which validate the use of biomaterials for the delivery of these newer therapeutics. For bone repair, a miR-29a inhibitor, intended to increase ECM deposition, was delivered with gelatin nanofibers [@bib130]. The investigators demonstrated the feasibility of this approach, as well as efficacy in terms of a slow release profile and sustained bioactivity of the miRNA inhibitor once released compared with a scrambled miRNA control. The Burdick lab has also begun investigating a hydrogel system for small interfering ribonucleic acid delivery [@bib131], but further studies are still ongoing. Therefore, this represents a promising area of research for improving the delivery of the next generation of therapeutics and should be explored for MI and PAD.

Finding the Optimal Therapy for MI and PAD Patients: Balancing Therapeutic Potential and Commercialization Challenges {#sec4}
=====================================================================================================================

Extensive research has validated the use of acellular biomaterials, but difficulties must still be overcome before implementation into the clinic. When considering incorporation of additional factors, an acellular approach is optimal for multiple reasons. Including cells dramatically reduces shelf life due to instability and significantly increases manufacturing expenses for a large-scale setting. The addition of growth factors encompasses many of these same issues, including reduced shelf life and high cost, but new manufacturing methods are being studied to overcome these obstacles. For example, Cochran and colleagues [@bib68], [@bib132] have developed an engineered HGF fragment with increased stability and lower cost of manufacturing, while maintaining its therapeutic effects. With new methods being optimized for growth factor delivery, these lower-cost options could result in more feasible biomaterial-based treatments for MI and PAD patients.

As discussed earlier, biomaterials may also be delivered alone and have produced significant improvements in animal models of MI and PAD. From a manufacturing perspective, a biomaterial-alone approach is the preferred method, as the increased costs and manufacturing time associated with additional therapeutics are negated. However, several studies previously mentioned suggest that a combinatorial approach may be more effective. Although current growth factor therapies may not be ideal for eventual translation to the clinic, due to difficult and expensive manufacturing, less expensive, engineered growth factors, like the one mentioned previously, or other therapeutics may augment the benefits of injectable biomaterials. The studies utilizing microvesicles, exosomes, or miRNAs alone have also demonstrated substantial therapeutic efficacy in MI and PAD animal models, but more research must be done to optimize the delivery of these factors. In conclusion, research must be conducted to investigate the delivery of additional therapeutics with biomaterials, but the added therapeutic efficacy must outweigh the additional costs.

Conclusions {#sec5}
===========

Acellular biomaterial-based therapies may be a solution for many patients experiencing MI and PAD. By harnessing the ability to engineer these biomaterials and employing the minimally invasive nature of many of these therapies, patients may soon receive treatments designed to stimulate tissue regeneration and improved muscle function. Although further research must be conducted to develop optimal biomaterial strategies, and manufacturing expenses must be carefully considered, the field is rapidly progressing toward identifying new treatments for MI and PAD patients.
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[^1]: bFGF = basic fibroblast growth factor; ECM = extracellular matrix; EPO = erythropoietin; FGF = fibroblast growth factor; G-CSF = granulocyte-colony stimulating factor; HGF = hepatocyte growth factor; IGF = insulin-like growth factor; MI = myocardial infarction; NRG = neuregulin; PAD = peripheral artery disease; PDGF-BB = platelet-derived growth factor BB; PEG = polyethylene glycol; PLGA = poly(lactic-*co*-glycolic acid); PNIPAAm = poly(*N*-isopropylacrylamide); rTIMP = recombinant tissue inhibitor of matrix metalloproteinase-3; SDF-1 = stromal cell-derived factor; UPy = ureidopyrimidinone; VEGF = vascular endothelial growth factor.

[^2]: CLI = critical limb ischemia; EF = ejection fraction; HF = heart failure; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume; PCI = percutaneous coronary intervention; other abbreviations as in [Table 1](#tbl1){ref-type="table"}.
